<DOC>
	<DOCNO>NCT01823185</DOCNO>
	<brief_summary>Clopidogrel crucial antiplatelet treatment patient undergo percutaneous coronary intervention ( PCI ) stent implantation one year PCI , prevent atherothrombotic complication . However , clopidogrel ineffective certain patient due genetic mutation CYP2C19 gene specific enzyme liver require metabolism clopidogrel . Therefore , purpose study test patient genetically bedside prescribe alternative drug Ticagrelor ( 90 mg twice daily ) prasugrel ( 10mg daily 5mg daily patient old 75 year body weight &lt; 60kg ) carrier allele 2 3 mutate gene .</brief_summary>
	<brief_title>Bedside Testing CYP2C19 Gene Treatment Patients With PCI With Antiplatelet Therapy</brief_title>
	<detailed_description>Clopidogrel crucial antiplatelet treatment patient undergo percutaneous coronary intervention ( PCI ) stent implantation one year PCI , prevent atherothrombotic complication . Clopidogrel convert active metabolite Cytochrome P2C19 ( CYP2C19 ) . However 30 % Saudi population carrier non functional CYP2C19*2 *3 allele impair CYP2C19 capacity , result decreased effectiveness Clopidogrel . These patient 42 % high risk major cardiovascular event ( MACE ) compare non carrier . Further 50 % MACE occur first 48 hour . Therefore Ticagrelor ( 90 mg twice daily ) prasugrel ( 10mg daily 5mg daily patient old 75 year body weight &lt; 60kg ) whose action dependent conversion CYP2C19 may alternative carrier non functional CYP2C19*2 *3 alleles . This might cost effective prevent patient form MACE . Therefore objective study ass efficacy , complication free survival , safety cost-effectiveness CYP2C19 genotype guide antiplatelet treatment strategy , use clopidogrel prasugrel ( Ticlid ) . All participant follow one year use follow questionnaire .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Chest Pain</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Purinergic P2 Receptor Antagonists</mesh_term>
	<criteria>Male &amp; female age 1870 year Patient present acute myocardial infarction 30 minute less 12 hour Patient eligible PCI Life expectancy less one year Previously Known genotype Receiving chemotherapy malignancy On dialysis receive immunosuppressive therapy autoimmune disease Hepatic impairment History bleed diathesis Receiving vitamin K antagonist therapy Confirmed hypertension Out normal range platelet count History major surgery Severe trauma fracture Pregnancy lactation Concomitant use simvastatin , cytochrome P450 3A4 inhibitor inducer Hypersensitivity clopidogrel ticagrelor prasugrel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Clopidogrel</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Prasugrel</keyword>
	<keyword>Platelet aggregation inhibitor</keyword>
	<keyword>Dammam University</keyword>
	<keyword>King Fahd Hospital</keyword>
	<keyword>Purinergic P2 receptor Antagonists</keyword>
</DOC>